Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1 6Phase 1/2 4Phase 3 3Phase NA 1Phase 2/3 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 1

Interventions

Radiotherapy 17Magnetic Resonance Spectroscopy 16Psychiatric Rehabilitation 13Cyclophosphamide 13Early Intervention, Educational 11Methotrexate 9Doxorubicin 9Counseling 9Biopsy 9Vincristine 8Cytarabine 7Carboplatin 7Specimen Handling 6Neoadjuvant Therapy 6Immunohistochemistry 6Gene Expression Profiling 6Dexamethasone 6Chemotherapy, Adjuvant 6Prednisolone 5Peripheral Blood Stem Cell Transplantation 5Leucovorin 5Immunoenzyme Techniques 5High-Energy Shock Waves 5Fluorouracil 5Filgrastim 5Colposcopy 5Cisplatin 5Busulfan 5X-Rays 4Polymerase Chain Reaction 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × NIH × oblimersen × Clear all
NCT00070343 2014-01-06

Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301

National Cancer Institute (NCI)

Phase NA Unknown
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡